Joined QIAGEN in 2005 and has worked in increasing positions of responsibility in Corporate Business Development until he was named in 2015 to the role of Senior Vice President, Corporate Business Development. In October 2019, Mr. Viola was appointed member of the Executive Committee and took on additional responsibilities for the Molecular Diagnostics Business Area, which involves QIAGEN’s activities supporting customers in clinical healthcare, and transitioned during this period to focus solely on Molecular Diagnostics beginning in early 2022. Prior to joining QIAGEN, Mr. Viola served as President and CEO of Nextal Biotechnologies Inc., a provider of technologies for protein crystallization, and when QIAGEN acquired Nextal in 2005 he joined as Director of Protein Crystallization. Moving to Business Development in 2007, Mr. Viola led efforts in Asia-Pacific, the Americas, Global M&A and Corporate Ventures. He completed a Bachelor of Science in Biochemistry from the University of Montreal, Canada.